Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas

American Journal of Surgical Pathology

Volumn 30, Issue 2, 2006, Pages 216-222

  Adeniran, Adebowale J ^a   Zhu, Zhaowen ^a   Gandhi, Manoj ^a   Steward, David L ^a   Fidler, James P ^b   Giordano, Thomas J ^c   Biddinger, Paul W ^a   Nikiforov, Yuri E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

BRAF; Nuclear features; RAS; RET PTC; Thyroid papillary carcinoma

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; PROTEIN RET;

ADULT; AGED; ARTICLE; CANCER STAGING; CORRELATION ANALYSIS; FEMALE; FROZEN SECTION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROSCOPIC ANATOMY; ONCOGENE RAS; POINT MUTATION; PROGNOSIS; QUANTITATIVE ANALYSIS; RELIABILITY; THYROID PAPILLARY CARCINOMA; TUMOR VOLUME; AGE; GENETICS; MIDDLE AGED; MUTATION; PAPILLARY CARCINOMA; PATHOLOGY; THYROID TUMOR;

ADULT; AGE FACTORS; CARCINOMA, PAPILLARY; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS;

EID: 33645232222     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pas.0000176432.73455.1b     Document Type: Article

References (39)

1. American Joint Committee on Cancer. Cancer Staging Manual, 6th ed. New York: Springer-Verlag, 2002.
2. Akslen LA, LiVolsi VA. Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma. Cancer. 2000;88:1902-1908.
3. Bongarzone I, Butti MG, Coronelli S, et al. Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res. 1994;54:2979-2985.
4. Bongarzone I, Vigneri P, Mariani L, et al. RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin Cancer Res. 1998;4:223-228.
5. Chevillard S, Ugolin N, Vielh P, et al. Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications. Clin Cancer Res. 2004;10:6586-6597.
6. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95:625-627.
7. Dean DS, Hay ID. Prognostic indicators in differentiated thyroid carcinoma. Cancer Control. 2000;7:229-239.
8. DeLellis RA, Lloyd RV, Heitz PU, et al, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs. Lyon, France: IARC Press, 2004.
9. De Micco C. Ras mutations in follicular variant of papillary thyroid carcinoma. Am J Clin Pathol. 2003;120:803;author reply 804.
10. Ezzat S, Zheng L, Kolenda J, et al. Prevalence of activating ras mutations in morphologically characterized thyroid nodules. Thyroid. 1996;6:409-416.
11. Flint A, Davenport RD, Lloyd RV. The tall cell variant of papillary carcinoma of the thyroid gland: comparison with the common form of papillary carcinoma by DNA and morphometric analysis. Arch Pathol Lab Med. 1991;115:169-171.
12. Frattini M, Ferrario C, Bressan P, et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene. 2004;23:7436-7440.
13. Fugazzola L, Mannavola D, Cirello V, et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf). 2004;61:239-243.
14. Giordano TJ, Kuick R, Thomas DG, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene. 2005. (in press)
15. Grieco M, Santoro M, Berlingieri MT, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 1990;60:557-563.
16. Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see comments]. Cancer. 1998;83:2638-2648.
17. Hundahl SA, Cady B, Cunningham MP, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer. 2000;89:202-217.
18. Johannessen JV, Sobrinho-Simoes M. The origin and significance of thyroid psammoma bodies. Lab Invest. 1980;43:287-296.
19. Johnson TL, Lloyd RV, Thompson NW, et al. Prognostic implications of the tall cell variant of papillary thyroid carcinoma. Am J Surg Pathol. 1988;12:22-27.
20. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454-1457.
21. Knauf JA, Ma X, Smith EP, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 2005;65:4238-4245.
22. Namba H, Rubin SA, Fagin JA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol. 1990;4:1474-1479.
23. Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab. 2003;88:4393-4397.
24. Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocr Pathol. 2002;13:3-16.
25. Nikiforov YE, Nikiforova MN, Gnepp DR, et al. Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident. Oncogene. 1996;13:687-693.
26. Nikiforov YE, Rowland JM, Bove KE, et al. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 1997;57:1690-1694.
27. Nikiforova MN, Caudill CM, Biddinger P, et al. Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas. Int J Surg Pathol. 2002;10:15-22.
28. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399-5404.
29. Prendiville S, Burman KD, Ringel MD, et al. Tall cell variant: an aggressive form of papillary thyroid carcinoma. Otolaryngol Head Neck Surg. 2000;122:352-357.
30. Puxeddu E, Moretti S, Elisei R, et al. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab. 2004;89:2414-2420.
31. Santoro M, Dathan NA, Berlingieri MT, et al. Molecular characterization of RET/PTC3: a novel rearranged version of the RET protooncogene in a human thyroid papillary carcinoma. Oncogene. 1994;9:509-516.
32. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003;22:4578-4580.
33. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch. 2004;444:572-576.
34. Sugg SL, Ezzat S, Rosen IB, et al. Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metab. 1998;83:4116-4122.
35. Tallini G, Santoro M, Helie M, et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res. 1998;4:287-294.
36. Viglietto G, Chiappetta G, Martinez-Tello FJ, et al. RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene. 1995;11:1207-1210.
37. Wreesmann VB, Ghossein RA, Hezel M, et al. Follicular variant of papillary thyroid carcinoma: genome-wide appraisal of a controversial entity. Genes Chromosomes Cancer. 2004;40:355-364.
38. Xu X, Quiros RM, Gattuso P, et al. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 2003;63:4561-4567.
39. Zhu Z, Gandhi M, Nikiforova MN, et al. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma: an unusually high prevalence of ras mutations. Am J Clin Pathol. 2003;120:71-77.